NextCure Inc expected to post a loss of 66 cents a share - Earnings Preview

NextCure

28/02/2023 02:27

* NextCure Inc  NXTC.OQ   NXTC.O  is expected to show no
change in
quarterly revenue when it reports  results on March 1
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for NextCure Inc is for
a
loss of 66 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NextCure
Inc is
$6​, above​ its last closing price of $1.62. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.62       -0.63      -0.68     Missed  -8.7
 Jun. 30 2022  -0.72       -0.72      -0.65     Beat    9.7
 Mar. 31 2022  -0.67       -0.67      -0.74     Missed  -10.7​
 Dec. 31 2021  -0.67       -0.67      -0.61     Beat    9.1
 ​​Sep.        -0.66       -0.67      -0.65     Beat    2.5
 30 2021                                                
 Jun. 30 2021  -0.62       -0.61      -0.65     Missed  -6.4​
 Mar. 31 2021  -0.61       -0.59      -0.60     Missed  -2.1
 Dec. 31 2020  -0.61       -0.60      -0.54     Beat    9.7
 This summary was machine generated February 28 at 02:27 GMT. 
All figures in US dollars  unless otherwise stated